Institutional members access full text with Ovid®

Share this article on:

MACULAR ATROPHY AND MACULAR MORPHOLOGY IN AFLIBERCEPT-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Kuroda, Yoshimasa, MD*; Yamashiro, Kenji, MD, PhD*,†; Ooto, Sotaro, MD, PhD*; Tamura, Hiroshi, MD, PhD*; Oishi, Akio, MD, PhD*; Nakanishi, Hideo, MD, PhD*; Miyata, Manabu, MD, PhD*; Hata, Masayuki, MD*; Takahashi, Ayako, MD*; Wakazono, Tomotaka, MD*; Yoshimura, Nagahisa, MD, PhD*; Tsujikawa, Akitaka, MD, PhD*,‡

doi: 10.1097/IAE.0000000000001765
Original Study: PDF Only

Purpose: To investigate the incidence and predictors of macular atrophy during treatment with aflibercept for neovascular age-related macular degeneration in Japanese patients.

Methods: This study included patients with treatment-naive subfoveal neovascular age-related macular degeneration treated from December 2012 through January 2015. Patients were treated with bi-monthly aflibercept injections after 3 monthly loading injections for the first year. Diagnosis of retinal pigment epithelial atrophy was made based on color fundus photography, spectral-domain optical coherence tomography, and fundus autofluorescence. Baseline characteristics and morphological features were analyzed for their association with the development of macular atrophy.

Results: This study included 123 eyes that had no baseline macular atrophy and treated with aflibercept injections for 12 months. Thirteen eyes (10.6%) developed new macular atrophy at 12 months. Logistic regression analysis showed that the presence of intraretinal fluid and thinner subfoveal choroidal thickness at baseline were associated with the development of macular atrophy after aflibercept treatment.

Conclusion: Macular atrophy developed in about 10% of eyes with neovascular age-related macular degeneration during 12 months of treatment with a fixed regimen of aflibercept. Intraretinal fluid and subfoveal choroidal thickness seem to be predictors for development of macular atrophy after anti-vascular endothelial growth factor (VEGF) therapy.

The presence of intraretinal fluid and thinner subfoveal choroidal thickness at baseline would be associated with the development of macular atrophy in patients with neovascular age-related macular degeneration during anti-vascular endothelial growth factor treatment.

*Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan;

Department of Ophthalmology, Red Cross Otsu Hospital, Otsu, Japan; and

Department of Ophthalmology, Kagawa University Faculty of Medicine, Miki, Japan.

Reprint requests: Kenji Yamashiro, MD, PhD, Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Kawahara, Shogoin, Sakyo, Kyoto 606-8507, Japan; e-mail: yamashro@kuhp.kyoto-u.ac.jp

Supported in part by the Japan Society for the Promotion of Science (JSPS), Tokyo, Japan (Grant-in-Aid for Scientific Research, no. 21592256), the Japan National Society for the Prevention of Blindness, Tokyo, Japan and the Innovative Techno-Hub for Integrated Medical Bio-imaging of the Project for Developing Innovation Systems, from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) in Japan.

S. Ooto: Alcon, Tokyo, Japan (financial support). A. Oishi: Alcon, Tokyo, Japan (financial support). N. Yoshimura: Canon, Tokyo, Japan (financial support); Santen, Osaka, Japan (financial support); Novartis, Tokyo, Japan (financial support); Bayer, Tokyo, Japan (financial support). A. Tsujikawa: Pfizer, Tokyo, Japan (financial support); Bayer, Tokyo, Japan (financial support); Novartis, Tokyo, Japan (financial support); Santen, Osaka, Japan (financial support); Senju, Osaka, Japan (financial support); Alcon, Tokyo, Japan (financial support); Nidek, Gamagori, Japan (financial support); Kowa, Nagoya, Japan (financial support); AMO Japan, Tokyo, Japan (financial support). The remaining authors have no conflicting interests to disclose.

© 2018 by Ophthalmic Communications Society, Inc.